bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
Alterations of the TGFb-sequestration complex member ADAMTSL1 levels are 
associated with muscular defects and rhabdomyosarcoma aggressiveness 
 
GaÃ«tan  Juban*2,  Adrien  Bertrand-Chapel*1,  Swann  Meyer*1,  Anita  Kneppers#2,  Paul1 
HuchedÃ©#1, Cindy Gallerne#1,3, Ruth Benayoun1, Enzo Cohen4, Alejandro Lopez-Gonzales1, 
Sabrina Ben Larbi2, Marion Creveaux1, Lucile Vaille1, AmÃ©lie Bouvier1, Marine ThÃ©odore4, Laura 
Broutier1,  AurÃ©lie  Dutour1,  Martine  Cordier-Bussat1,  Jean-Yves  Blay1,  Nathalie 
Streichenberger5, CÃ©cile Picard5, NadÃ¨ge Corradini1,6, ValÃ©rie Allamand4, Perrine Castets$,3, 
RÃ©mi Mounier$,2, Marie Castets$1,6. 
 
1Childhood Cancer & Cell Death (C3), LabEx DEVweCAN, Institut Convergence Plascan, Centre 
LÃ©on BÃ©rard, Centre de Recherche en CancÃ©rologie de Lyon (CRCL), UniversitÃ© Claude Bernard 
Lyon 1, INSERM 1052, CNRS 5286, 69008 Lyon, France. 
2Institut NeuroMyoGÃ¨ne, UniversitÃ© Claude Bernard Lyon 1, CNRS UMR 5261, INSERM U1315, 
UniversitÃ© de Lyon, Lyon, France. 
3Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, 1 
Rue Michel Servet, 1211, Geneva, Switzerland. 
4Sorbonne UniversitÃ©, INSERM, Institut de Myologie, Centre de Recherche en Myologie, Paris, 
France. 
5Department of Pathology, HÃ´pital Femme-MÃ¨re-Enfant, Hospices Civils de Lyon, Claude 
Bernard Lyon 1 University, 69002 Lyon, France. 
6Department of Translational Research in Pediatric Oncology PROSPECT, Centre LÃ©on BÃ©rard, 
69008 Lyon, France. 
 
*co-first authors 
$ co-last authors 
Corresponding authors: marie.castets@lyon.unicancer.fr ; remi.mounier@univ-lyon1.fr 
 
   

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
ABSTRACT 
 
Rhabdomyosarcoma (RMS) is the most frequent form of paediatric soft-tissue sarcoma and 
remains a medical challenge, holding in failure current therapeutic strategies. RMS shares 
histological features with cells of the muscle lineage and this cancer is thought to arise from 
malignant  transformation  of  myogenic  precursors.  It  has  been  proposed  that  RMS  and 
myogenesis could represent the â€œJekyll and Hydeâ€ of skeletal muscle. The underlying idea is 
that some early steps of myogenic differentiation are blocked in RMS, and that understanding 
how the normal process has gone awry could help to decipher the biological underpinnings of 
tumorigenesis and tumor escape.  
 
It is widely agreed that extracellular matrix (ECM) interferes in skeletal muscle regeneration 
and that defects in ECM components are clinically significant. The challenge is now to decipher 
actors and mechanisms responsible for the transmission of signals to muscle cells and the 
subsequent alterations that could be associated with RMS.  
 
Using an original transgenic mice model, we show here that ADAMTSL1 is involved in skeletal 
muscle regeneration. As previously reported for other members of its family, ADAMTSL1 is 
part of the TGF-b-ECM-sequestering complex and likely positively regulates TGF-b-pathway 
activity. Last, we observed that ADAMTSL1 expression behaves as a strong prognostic factor 
in the aggressive fusion-positive RMS and correlates with a neural-like phenotype of tumor 
cells, resulting from gain of SMAD2/3/4 targets. 
 
 
   

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
INTRODUCTION 
 
Rhabdomyosarcoma  (RMS)  is  the  most  frequent  form  of  pediatric  soft-tissue  sarcoma, 
accounting  for  5%  of  solid  pediatric  tumors1.  Two  major  histological  subtypes  are 
distinguished: alveolar RMS (ARMS) driven by PAX3-FOXO1 or PAX7-FOXO1 translocations in 
80% of cases, and embryonal RMS (ERMS), which are genetically heterogeneous. RMS shares 
histological features with cells of the skeletal muscle lineage and high expression levels of 
myogenic proteins such as MyoD, Myogenin, and Desmin are also observed in tumors. RMS 
are thought to arise, at least in part, from malignant transformation of skeletal muscle 
precursors2. The notion that the molecular pathogenesis of myogenic cancers, and notably 
RMS,  may  share  similarities  with  muscular  dystrophies  has  begun  to  emerge3.  Indeed, 
increased  propensity  to  develop  RMS  has  been  reported  in  some  murine  models  of 
dystrophies4. This is thought to result notably from the induction of inflammation, fibrosis and 
oxidative stress that accompany both tumor development and muscular dystrophies. Some of 
the molecules described as deregulated in dystrophies have also been connected to RMS 
occurrence  and  reciprocally.  Intragenic  deletions  in  dystrophin,  mutated  in  Duchenne 
Muscular Dystrophy, are one of the underlying causes of tumor escape in RMS5. Proteins 
related to DUX4, whose gain of expression is now pointed to be largely responsible for Facio-
Scapulo-Humeral  Dystrophy  (FSHD),  are  also  expressed  in  human  RMS  cell  lines6,7. 
Reciprocally, significant enrichment of cancer-related genes has been observed among genes 
altered in FSHD muscle cells, thereby suggesting that pathogenesis of dystrophies and cancers 
may indeed be driven by modifications of a common set of genes and associated-signaling 
pathways. 
 
Among these signaling pathways, figures Transforming Growth Factor beta (TGF-Î²) one.  TGF-
Î² is a polypeptide that regulates several aspects of cells physiology in different tissues and has 
multiple  effects  in  pathological  conditions.  In  skeletal  muscle,  it  has  been  involved  in 
regulation of muscle growth/size, myogenesis and possibly even stemness8. This cytokine 
affects skeletal muscle function in diseases, as exemplified with fibrosis in dystrophic muscles9 
and recently with muscle cachexia observed in some cancers8,10,11. TGF-Î² also plays a complex 
role in tumor progression, since it is considered as a tumor suppressor in the early steps of 
tumorigenesis, and as an oncogene in advanced tumors11. It has notably been shown to inhibit 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
tumor cells differentiation and to promote proliferation in RMS12. TGF-Î² is secreted as a latent 
cytokine that is further sequestered by extracellular matrix (ECM) components. Indeed, the 
three TGF-Î² isoforms are synthetized as pro-proteins. After proteolytical cleavage, the pro-
domain, called LAP (Latency-Associated Peptide (LAP)), remains non-covalently associated to 
the mature TGF-Î² moieties, forming a complex called Small Latent Complex (SLC)13. In the 
endoplasmic  reticulum,  this  SLC  complex  covalently  interacts  with  Latent-Transforming 
Growth Factor-b binding proteins (LTBP) to form the Large Latent Complex (LLC). Since LTBP1, 
2, 3 and 4 are microfibril-associated proteins that bind to fibrillin, the LLC is incorporated to 
the ECM and TGF-Î² is stored in this latent form that is unable to bind to cell-surface 
receptors13. Once released from the LAP pro-domain, TGF-Î² binds to TÎ²RI and TÎ²RII receptors, 
which trigger the so-called non-canonical and canonical SMAD signaling pathway that leads to 
changes in gene expression.  
 
The regulation of TGF-Î² bioavailability within the ECM is therefore crucial for appropriate 
mobilization and activation of this cytokine. Deciphering the mechanisms underlying the 
mobilization of latent TGF-Î² from this local reservoir could shed new light on the role exerted 
by ECM on skeletal muscle homeostasis on one hand, and on alterations associated to 
tumorigenesis in RMS on the other hand. Very little is known about alterations of ECM in RMS, 
but some ECM proteins have been characterized as biomarkers14.  
 
Here, we decided to study the role of ADAMTSL1 [a disintegrin and metalloprotease domain 
with thrombospondin motifs)-like 1] in these processes. ADAMTSL1 is the first identified 
member of a family of ECM-associated proteins that are closely related to ADAMs and 
ADAMTS metalloproteinases, but devoid of enzymatic activity15. The role of ADAMTSL1 in 
mammals  remains  unknown.  Interestingly,  high  expression  levels  of  ADAMTSL1  were 
detected/described in skeletal muscle15. Moreover, 3 of the 7 members of the ADAMTSL 
family,  namely  ADAMTSL2,  3  and  6,  are  part  of  the  ECM  complex  regulating  TGF-Î² 
bioavailability16â€“18. In line with these issues, we show here that ADAMTSL1 contributes to 
skeletal muscle homeostasis by modulating TGF-b bioavailability, and that the subsequent 
impairment of its function is involved in RMS phenotype, and notably behaves as a prognostic 
factor in the most aggressive fusion-positive ones. 
 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
RESULTS 
 
Loss of ADAMTSL1 induces mild spontaneous muscular phenotype during ageing but is 
involved in muscle regeneration as a FAP-secreted protein. 
Since ADAMTSL1 was described as mostly expressed in skeletal muscles15, we analysed its 
function in this tissue by characterizing an original Adamtsl1 KO mice, generated via MMRRC 
repository, through constitutive excision of exon 1 (Figure 1A). We validated the deletion of 
Adamtsl1 exon 1 in progeny using specific primers (Figure S1A). Adamtsl1+/- and Adamtsl1-/- 
mice were born at expected mendelian frequencies, healthy and fertile.  
We confirmed that the transcription of Adamtsl1 is significantly turned off in skeletal muscles 
of homozygous KO animals as compared to their wild-type (WT) littermates (Figure 1A). Of 
note, ADAMTSL1 KO mice are identifiable by a kink at the end of the tail (Figure S1B). Loss of 
ADAMTSL1 is not associated with obvious changes in skeletal muscle organization in young 
animals (data not shown). However, defects can be observed in KO animals from 6 months of 
age, with a 20% decrease in mean muscle fiber diameter, especially in fast contraction type 
IIb fibers (Figure 1B). This muscle fiber hypotrophy is associated with a slight atrophy of the 
Gastrocnemius+Soleus assembly at 12 months only (Figure S1C). Consistent with progressive 
muscle weakening during ageing, a typical hunchback is observable in one-year Adamtsl1-/- 
animals (Figure S1D). These changes were not associated with any difference in the number 
of Pax7+ cells nor in the percentage of centronucleated fibers, suggesting that the defects may 
likely result in part from alterations of muscle cell differentiation (Figure S1E-F). We then 
wondered what its contribution in muscle regeneration could be. To do so, we compared 
skeletal muscle regeneration after cardiotoxin (CTX) injection in adult KO mice and their wild-
type counterparts. As shown on Figure 1C, ADAMTSL1 loss is associated with defects in muscle 
regeneration characterized by lipid droplets accumulation. These defects are not due to 
intrinsic failure of Adamtsl1 KO satellite cells to differentiate and fuse, as shown by their ability 
to do so when isolated in vitro (Figure 1D). Of note, the number of Pax7+, a readout of satellite 
cell self-renewal, are similar in KO and WT animals 28 days post-CTX injection (Figure S1G). 
Since satellite cells phenotype does not seem to be intrinsically affected by ADAMTSL1 loss, 
we sought to identify whether this matrix protein was secreted by a specific skeletal muscle 
cell population. Using single-cell analysis, we observed that ADAMTSL1 is mostly expressed by 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
Fibro-Adipogenic Precursors (FAP, Figure 1E) and that its expression is increased during 
regeneration in this population (Figure 1F). 
 
Then, loss of FAP-produced ADAMTSL1 is associated with muscular defects during ageing and 
regeneration. 
 
ADAMTSL1 belongs to the FBN1 matrix complex regulating TGF availability. 
To clarify the role of ADAMTSL1 in muscle homeostasis, we decided to study it in the context 
of muscular dystrophy. Indeed, repeated lesions of muscle fibers in patients suffering from 
Duchenne  dystrophy  trigger  permanent  regeneration  cycles,  finally  leading  to  muscle 
fibrosis19. By integrating public transcriptomic data from the analysis of musclesâ€™ biopsies of 
Duchenne patients at different stages of the disease, we observed that ADAMTSL1 expression 
increases sequentially at the three stages of the disease, i.e. mild, moderate and severe (Figure 
2A). The same trend is observed for ADAMTSL3 and 4, although less significantly, but not for 
ADAMTSL2 (Figure S2A). On the contrary, the expression of ADAMTSL5 decreases under the 
same conditions. Interestingly, ADAMTSL2, 3 and 6 have been described as matrix proteins, 
associated with the TGF-Î²-fibrillin sequestering complex16â€“18, and TGF-Î² is one of the main 
contributors to the muscle fibrosis observed in the context of muscular dystrophy20. Thus, it 
was tempting to speculate that ADAMTSL1 could play a role in muscle homeostasis by 
regulating TGF-Î² bioavailability. As shown on Figure 2B, ADAMTSL1 colocalizes with LTBP1 and 
FBN1 in the muscle ECM of patients with dystrophy. In addition, we used the PROGENy 
method to infer downstream apoptotic-response footprint from perturbation-response genes 
indicative of the TGF-Î² activity21. This score is significantly increased in moderate grade 
dystrophic muscle samples as compared to mild grade, and even more significantly between 
severe and mild grades (Figure S2B), consistent with the activation of this pathway in this 
pathological context22. As shown in Figure 2C, TGF-Î² pathway activity is significantly correlated 
with ADAMTSL1 expression notably in the group of patients with mild dystrophy (Figure 2C). 
These data suggest that ADAMTSL1 may play a positive role in the regulation of TGF-Î² 
bioavailability in muscles and are consistent with analyses performed in mice showing that 
the expression of 18% of the major target genes of the TGF pathway is significantly altered in 
muscles from KO mice as compared to wild-type mice (Figure 2D). 
 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
Altogether, these data indicate that ADAMTSL1 likely replays a role in muscle regeneration via 
regulation of TGF-Î² bioavailability. 
 
ADAMTSL1  expression  positively  correlates  with  prognosis  in  fusion-positive 
rhabdomyosarcoma and with expression of SMAD3/4 neural-like targets.  
RMS are thought to result at least in part from defects in the process of myogenesis, with a 
premature  arrest  of  muscle  cell  differentiation1,23,24.  Considering  the  role  of  TGF-Î²  in 
tumorigenesis and its impact on muscle differentiation in RMS12,25,26, we then wondered 
whether alterations in ADAMTSL1 expression might play a role in RMS. Integration of RNAseq 
data indicates that ADAMTSL1 expression is significantly lower in RMS than in skeletal muscle 
samples, in two independent cohorts (Figure 3A and Figure S3A). To go further, we analyzed 
the clinical value of ADAMTSL1 expression. Interestingly, the integration of transcriptomic 
data indicates that ADAMTSL1 expression is positively correlated with the prognosis in the so-
called fusion-positive RMS (FP-RMS), expressing the Pax3/7-FOXO1 translocation, but not in 
the fusion-negative RMS (FN-RMS), which lack it (Figure 3B-C). Similarly, a high level of 
methylation of the ADAMTSL1 locus is associated with a poor prognosis in FP-RMS, but not in 
FN-RMS  (Figure  S3B-C).  To  clarify  the  molecular  identity  and  origin  of  the  prognostic 
differences observed between tumors with high and low levels of ADAMTSL1, we performed 
a differential expression (DE) analysis between these two subgroups. Of the 270 DE genes 
corresponding to the intersection of two independent cohorts (Figure S3D), we observed that 
64.7%  are  more  expressed  in  the  ADAMTSL1-high  tumors  group  as  compared  to  the 
ADAMTSL1-low group, as shown on heatmaps (Figures 3D and S3E). Functional gene set 
enrichment indicate that the ADAMTSL1-high tumors group is robustly defined by neural-
related pathways, especially some involved in regulation of cell migration/adhesion (Figure 
3E).  Accordingly,  but  counterintuitively  to  the  positive  prognostic  value  of  ADAMTSL1, 
ADAMTSL1 expression by 3T3 fibroblasts promotes migration of rhabdomyosarcoma cells of 
the RH30 fusion-positive line in Boyden chamber experiments (Figure 3F). Last, RMS tumors 
expressing high level of ADAMTSL, but not those with low levels of this gene, are significantly 
enriched  in  target  genes  of  SMAD2/3/4,  which  are  the  transcription  factors  activated 
downstream of TGF-Î² (Figure 3G). 
 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
Then, ADAMTSL1 behaves as a prognostic factor in FP-RMS and likely interfere with tumor cell 
properties through regulation of TGF-Î² pathway activity. 
 
DISCUSSION 
RMS account for 5% of all pediatric tumors. Intensive therapeutic management has improved 
their 5-year survival from 25% in 1970 to 60-70% since 20002. However, outcome has reached 
a plateau since that time, despite many randomized chemotherapy trials. Moreover, 2/3 of 
cured children suffer from long-term side effects of both disease and treatments2,27. This 
underscores the need to elucidate molecular mechanisms of these malignancies to develop 
new  therapeutic  strategies,  both  beneficial  for  patients  in  therapeutic  failure  and  with 
reduced toxicity. 
 
It has been proposed that RMS and myogenesis could represent the â€œJekyll and Hydeâ€ of 
skeletal muscle1. The underlying idea is that some early steps of myogenic differentiation are 
blocked in RMS: understanding how the normal process has gone awry could help to decipher 
the biological underpinnings of tumorigenesis and of tumor escape. 
Here, we show that ADAMTSL1, whose function was yet undefined, likely plays a role in muscle 
regeneration as a matrix protein, through regulation of the TGF-Î² pathway, and that alteration 
of its expression has a direct impact on FP-RMS aggressiveness. 
 
The role of ECM in skeletal muscle regeneration is not well understood, but it is widely agreed 
that alterations in ECM components are clinically significant. Along this line, two other 
members of the ADAMTSL family, namely ADAMTSL2 and 6, have been linked to genetic 
diseases of the Marfanoid spectrum, with mutations identified respectively in geleophysic 
dysplasia and thoracic aortic aneurysm16,28. Although not related to skeletal muscular defects, 
both proteins were also shown to be part of the FBN1 complex regulating the bioavailability 
of  TGF-Î²17.  Moreover,  ADAMTSL2  was  directly  identified  as  a  negative  regulator  of 
myofibroblast differentiation through inhibition of TGF-Î²29. Similarly, KO of ADAMTSL3 is 
associated with severe cardiac defects in mice, which result from an increase in TGF-Î² 
signalling, subsequently impairing myofibroblasts differentiation upon heart failure18. While 
these data suggest a conserved role of the 6 members of the ADAMTSL family in the regulation 
of TGF-Î² release, our results indicate that ADAMTSL1 may play the opposite role, by acting as 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
a positive regulator of the TGF-Î² signalling pathway: ADAMTSL1 could thus promote TGF-Î² 
release rather than its sequestration in the matrix. Consistently, fatty deposits similar to those 
observed  in  ADAMTSL1  KO  mice  after  injury  were  observed  in  transgenic  mice  that 
overexpress the human TGF-Î²-sequestering LTBP4 protein30, suggesting that ADAMTSL1 and 
LTBP4 may have antagonistic function on TGF-Î² pathway. Moreover, ADAMTSL1 expression 
correlates with TGF-Î² activation level in patients with Duchenne dystrophy, and its expression 
increases with disease severity: it remains however to be determined whether gain of 
ADAMTSL1 is causally involved in muscle degeneration observed in this pathology, or if it is a 
consequence of muscle fibrosis. 
 
Presence of a regenerative microenvironment in skeletal muscle, coupled with oncogenic 
alterations in cells, was shown to be sufficient to favor FN-RMS tumorigenesis in mice31. FBN2 
was also shown to have a prognostic value in FN-RMS, although through a yet undefined 
mechanism, but further highlighting the clinical relevance of ECM defects in RMS14. In contrast 
to the gain of ADAMTSL1 observed in dystrophic muscle samples, we show that the loss of 
ADAMTSL1 is highly significantly correlated with tumor aggressiveness but solely in FP-RMS, 
which are the most resistant to treatments2. Of note, this prognostic value is not only visible 
at the transcriptomic level, but also at the DNA methylation one, suggesting that the alteration 
of ADAMTSL1 expression in tumors may result from epigenetic modifications. Bioinformatic 
analyses  indicate  that  ADAMTSL1  expression  is  positively  correlated  with  a  neural-like 
phenotype,  which  has  been  previously  described  by  others  in  FP-RMS24.  It  had  been 
established  that  the  neuronal  guidance  activity  of  MADD-4,  the  C.  elegans  ortholog  of 
ADAMTSL1, was dependent on the presence of the netrin-1 receptor, DCC32. Interestingly, DCC 
is one of the neuronal genes significantly enriched in the ADAMTSL1-high tumor group, 
suggesting that some mechanisms of action may be conserved across species. The oncogenic 
valence of the FP-RMS neural state has not been described so far, but we have shown here 
that it could be associated with a higher migratory ability. Further analyses are however 
needed to understand how this observation may be compatible with the better prognosis of 
FP-RMS with the highest ADAMTSL1 expression. Along this line, it was previously shown that 
ADAMTSL1 may play an oncogenic role in chondrosarcoma through positive regulation of 
proliferation33, suggesting a pleiotropic role of this protein on tumor cell phenotype, which is 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
probably an indirect consequence of the complex role of TGF-Î² in tumor initiation and 
escape11. 
 
If the precise role of ADAMTSL1 in muscular dystrophies and RMS remains to be fully 
established, our work makes it a protein worth studying to understand how deregulations of 
the  skeletal  muscle  matrix  composition  can  create  a  deleterious  microenvironment, 
particularly conducive to tumor escape. 
 
   

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
MATERIAL AND METHODS 
 
Design of an ADAMTSL1 knock-out model 
The B6;129S5-Adamtsl1tm1Lex/Mmucd mouse strain presenting a constitutive deletion of the 
first exon of ADAMTSL1 was obtained from MMRRC. In brief, targeting vector was constructed 
using a fragment of ADAMTSL1 gene around exon 1 (NCBI accession: AK045085). Embryonic 
stem cell electroporation, selection, and culture, as well as generation of chimaeric mice and 
Southern blot analysis were performed in the MMRRC according to classical procedures 
(https://www.mmrrc.org/catalog/sds.php?mmrrc_id=32134). Heterozygous mice were then 
backcrossed at least 10 times in a C57BL/6 background. Double heterozygous ADAMTSL1+/- 
mice of the offspring were interbred to generate mice homozygous for the ADAMTSL1 exon 1 
deletion. Routine genotype analysis of mice was performed by PCR assay on DNA purified from 
tail biopsies (Extract N-Amp Tissue PCR kit, Sigma Aldrich). Wild-type and KO mutant alleles 
were distinguished using primers available on request. CT-Scan was performed on the animal 
imaging platform of CRCL. All experiments were performed in accordance with the relevant 
guidelines and regulations of the animal ethics committee (Authorization no. CLB-2015-024; 
accreditation of laboratory animal care by CECCAPP, ENS Lyon-PBES). 
 
Quantitative RTâ€“PCR 
Total RNA was extracted with the RNeasy Fibrous Tissue Mini Kit (Qiagen) and 1â€‰Âµg was 
reverse transcribed using the iScript cDNA Synthesis kit (Bio-Rad). Real-time quantitative RTâ€“
PCR was performed on a LightCycler 2.0 apparatus (Roche) using the Light Cycler FastStart 
DNA Master SYBERGreen I kit (Roche). Oligonucleotide sequences are available on request. 
Profiling of TGF-Î² targets was performed using the RTÂ² Profilerâ„¢ PCR Array Pig TGF-Î² Signaling 
Targets kit from Qiagen following manufacturersâ€™ instructions. 
Skeletal muscle injury 
Prior  injection  of  CTX  (12â€‰mM  in  saline,  Latoxan#L8102),  mice  were  anesthetized  by 
intraperitoneal injection of ketamine at 0.1â€‰mg/g body weight and xylazine at 0.01â€‰mg/g body 
weight diluted in saline solution. 50â€‰Î¼l of CTX was then injected into Tibialis Anterior muscles 
to induce injury, and mice were euthanized 0, or 28 days after the injury.  
 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
Satellite cell cultures â€“ in vitro model of adult myogenesis 
Skeletal muscle myoblasts derived from WT and KO ADAMTSL1 mice were isolated using the 
Satellite Cell Isolation Kit MACS protocol (Miltenyi Biotec), as described previously34. 
MACS isolated Satellite cells were seeded onto Gelatin (Sigma #G1393) coated supports at 
3000 cells/cm2 and amplified â‰¤3 passages in proliferation medium. After amplification, MuSC 
progeny (i.e., myoblasts) were trypsinized and plated at indicated densities onto Matrigel 
coated supports. To induce differentiation, proliferation medium was removed and replaced 
by differentiation medium (DMEM F12, 2% Horse serum (HS) (Gibco #16050130), and 1 % PS).  
 
Histological and immunohistochemistry analyses on muscle cryosections and cell cultures 
For  immunohistochemical  analyses,  muscles  of  interest  were  isolated,  embedded  in 
tragacanth gum (VWR #ICNA0210479280), frozen in liquid nitrogen cooled isopentane, and 
stored at -80Â°C until use. 10 Âµm-thick cryosections were prepared for hematoxylin-eosin (HE) 
staining and immunolabeling. HE staining was used to assess the efficiency of CTX injections, 
and muscles were only kept for further analyses if â‰¥75% of the muscle area consisted of 
centrally nucleated fibers. 
For lipid coloration, sections were fixed in 4% formaldehyde at 4Â°C during 30 min, and then 
stained with Sudan Black (Sigma-Aldrich Corp, St. Louis, MO, USA) for 60 minutes. Light 
microscopy was performed using an upright microscope (Leica and Olympus), and pictures 
were captured using a monochrome camera (DS-Ri1, Nikon).  
For immunohistochemistry, muscle cryosections were stained with ADAMTSL1 (Invitrogen 
MA1-41249), LTBP1 (Abcam ab78294), FBN1 (Abcam ab53076), Laminin (Abcam ab11575) and 
MHCIIA (DSHB SC-71) antibodies as described previously36. They were mounted in Vectashield 
DAPI (Vectorlabs) and observed with an Axiophot microscope (Zeiss). Images were captured 
using the MetaView software (Ropper Scientific). For identification of satellite cells, sections 
were  fixed  for  20  min  in  4%  paraformaldehyde  (PFA)  at  Room  Temperature  (RT),  and 
permeabilized for 6 min in 100% methanol at -20Â°C. After antigen retrieval for 2*5 min in 10 
mM Citrate buffer at 90Â°C, sections were saturated in 4% BSA for 2 hr at RT. Sections were 
then co-labelled overnight at 4Â°C with primary antibodies directed against Paired Box 7 (Pax7; 
DSHB; 1:50) and Laminin Î±1 (Sigma-Aldrich #L9393; 1:100) in 2% BSA. Secondary antibodies 
were coupled to FITC, Cy3 or Cy5 (Jackson ImmunoResearch Inc.; 1:200) and incubated for 45-
60 min at 37Â°C. Nuclear counterstain was performed by 10 sec incubation with Hoechst 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
(Sigma-Aldrich #14533; 2 ÂµM), and coverslips were mounted with Fluoromount G (Interchim, 
#FP-483331). 
 
For fusion assay, cultured cells were fixed for 10 min in 4% PFA at RT, permeabilized for 10 
min in 0.5% Triton X-100 in PBS, and saturated in 4% BSA for 1 hr at room temperature (RT). 
Cells were then incubated overnight at 4Â°C with primary antibodies directed Desmin (Abcam 
#Ab32362; 1:200) in 2% BSA. Secondary antibodies were coupled to FITC, Cy3 or Cy5 (Jackson 
ImmunoResearch Inc.; 1:200) and incubated for 45-60 min at 37Â°C. Nuclear counterstain was 
performed by 10 sec incubation with Hoechst (Sigma-Aldrich #14533; 2 ÂµM), and cells were 
covered with Fluoromount G (Interchim, #FP-483331).  
Randomly chosen fields of view from sections or cells cultured on removable chamber slides 
were acquired using a Zeiss Axio Imager Z1 connected to a Coolsnap Myo camera. For each 
condition of each experiment, at least 5-10 randomly chosen fields of view were counted. The 
fusion index was calculated as the percentage of nuclei within a cell containing â‰¥2 nuclei.  
 
RT-qPCR analysis in various cell populations FACS-sorted from Tibialis Anterior muscle 
Muscle cell populations were FACS-sorted as previously described37. Briefly, TA muscles were 
dissociated and digested in DMEM/F12 medium (GIBCO) containing 10 mg/ml of collagenase 
B and 2.4 U/ml Dispase II (Roche Diagnostics) for 30 min at 37Â°C under agitation and passed 
through a 30 Âµm cell strainer (Myltenyi Biotec). CD45pos and CD45neg cells were separated after 
incubation with mouse CD45 MicroBeads (Myltenyi Biotec) using a MS column (Myltenyi 
Biotec) on a MiniMACS Separator (Myltenyi Biotec). CD45pos cells were incubated with mouse 
FcR Blocking Reagent (Myltenyi Biotec) for 20 min at 4Â°C in PBS 2% FBS and stained with PE-
Cy7-conjugated anti-CD45 (25-0451-82, eBioscience), Alexa Fluor 647-conjugated anti-CD64 
(139322, Biolegend) and PE-conjugated anti-Ly6C (12-5932-82, eBioscience) antibodies for 30 
min  at  4Â°C.  CD45neg  cells  were  stained  with  PE-Cy7-conjugated  anti-CD45,  PerCP-Cy5.5-
conjugated anti-Sca-1 (45-5981-82, eBioscience), Alexa Fluor 647-conjugated anti-a7-integrin 
(AB0000538, AB lab, University British Columbia), PE-conjugated anti-CD31 (12-0311-82, 
eBioscience) and FITC-conjugated anti-CD34 (11-0341-82, eBioscience) antibodies for 30 min 
at 4Â°C. After addition of DAPI (BD Biosciences) to exclude dead cells, live cells were sorted 
using a FACS Aria II cell sorter (BD Biosciences). 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
Total  RNA  was  isolated  using  NucleoSpin  RNA  Plus  XS  kit  (Macheray-Nagel)  and  retro-
transcribed into cDNA with SuperScript II Reverse Transcriptase (Invitrogen). Quantitative PCR 
was realized in triplicate on a CFX Connect Real-Time PCR Detection System (Bio-Rad) using 
LightCycler 480 SYBR Green I Master kit (Roche Diagnostics). Calculation of relative expression 
was determined by the Bio-Rad CFX ManagerTM software and fold change was normalised as 
!âˆ†!"#$!"!%&
Normalised Relative Quantity (or Î”Î”Cq) for each series, as	ð‘ð‘…ð‘„ =  where T is the 
!âˆ†!"â€™$!"!%&
target sample, Cal is the calibrator value (i.e. the mean of all sample Cqs of the series) and R 
is the housekeeping gene Cyclophilin A. Sequence of primers used were as follows: 5â€™- 
TGGCTCAGAATGAAGCAGGG-3â€™ (Adamtsl1 fwd), 5â€™- AGTAAACACCTGAGTCGCGG-3â€™ (Adamtsl1 
rev),  5â€™-  GTGACTTTACACGCCATAATG  -3â€™  (Cyclophilin  A  fwd)  and  5â€™- 
ACAAGATGCCAGGACCTGTAT -3â€™ (Cyclophilin A rev). 
 
Cell culture and Migration Assays 
3T3 and RH30 were cultured according to manufacturersâ€™ instructions. 3T3 stably expressing 
the short isoform of ADAMTSL1 tagged with GFP (available on request) were established using 
JetPrime and selected on the basis of their resistance to puromycin. 
Transwell migration assay was used to evaluate the migration capacity of the cells. 3Ã—â€‰104   3T3 
fibroblasts, stably overexpressing, or not, ADAMTSL1, were seeded in 24 well plate. After 3 
days,  Boyden  chambers  (8â€‰Âµm  pore  size,  Corning  #353097)  were  added  in  3T3  wells. 
5â€‰Ã—â€‰104 FP-RMS RH30 were seeded in the insert chamber. After 24 hours, RH30 cells were 
washed with PBS1x, then methanol-fixed for 15â€‰min and stained with crystal violet (0.1%) for 
20â€‰min. The quantification of cell migration was determined using ImageJ software. 
 
Public scRNA-seq data of muscle tissue 
UMAP of cell types and ADAMTSL1 expression were made using harmony integrated data 
collected by the Single-Cell Muscle Project (scMuscle)38, which is available for download at 
https://datadryad.org/stash/dataset/doi:10.5061%2Fdryad.t4b8gtj34. 
 
Public microarray (gene expression and methylation) datasets 
GSE109178 (cohort 1, DMD samples) and GSE28511 (cohort 3, skeletal muscle and RMS 
samples)  datasets  were  downloaded  on  GEO  (www.ncbi.nlm.nih.gov/geo/),  then  log2-

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
transformed.  Raw  CEL  files  of  ETABM-1202  dataset39  (cohort  4)  were  downloaded  on 
ArrayExpress  (https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-TABM-1202),  and 
were normalized using the Robust Multiarray Average (RMA) algorithm (oligo R library v 
1.58.0)40. The GSE167059 methylation dataset (cohort 5) used for survival analysis was 
downloaded on R2 Cancer (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi).  
 
Generation and processing of RNA-seq datasets 
St Jude RMS 
HTseq count files of St Judeâ€™s RMS tumors (cohort 6) were downloaded on the St Jude Cloud 
platform (https://www.stjude.cloud) and generated as described41. 
 
Inhouse RMS cohort (cohort 2) 
Tissue banking and research were conducted according to national ethics guidelines, after 
obtaining the written informed consent of patients. For RNA-seq library construction of cohort 
3, total RNAs from tissues were isolated using the AllPrepÂ® DNA/RNA FFPE kit (Qiagen, cat. no. 
80224) following manufacturerâ€™s instructions. Libraries were prepared with Illumina Stranded 
mRNA Prep (Illumina, cat. no. 20040534) following recommendations. Quality was further 
assessed using the TapeStation 4200 automated electrophoresis system (Agilent) with High 
Sensitivity D1000 ScreenTape (Agilent). All libraries were sequenced (2Ã—100 bp) using Agilent 
SureSelect RNA XTHS2 All Exon V8 (Agilent, cat. no. G9991A) according to the standard Agilent 
protocol. 
Quality control of reads was performed using FastQC (v.0.11.9)42, followed by trimming of 
Illumina adapter sequences with Cutadapt (v.3.4)43 using the -a CTGTCTCTTATACACATCT and 
-A CTGTCTCTTATACACATCT parameters. Reads were mapped to the GRCh38 human genome 
using â€œtwo-passâ€ mode STAR (v.2.7.9)44, with Ensembl v104 annotations. Gene counts were 
then computed using HTseq-count (v.0.13.5)45 with the following parameters: â€œ--order posâ€ 
and â€œ--stranded reverseâ€. 
 
Data normalization of both datasets 
HTseq count files were then loaded in R (v 4.2.0) and two filtration steps were applied using 
the annotations of org.Hs.eg.db (v 3.15.0)46: genes with low counts (less than 10 reads across 
samples) were removed; non-protein-coding genes were removed. Filtered gene counts were 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
converted into a DESeq247 object with the design parameter set to account for the sample 
type (RMS/embryonal muscle/fetal muscle) in the case of the Inhouse cohort, and for the 
fusion status (FNRMS/FPRMS) in the cohort 6. Counts were then normalized with vst using 
â€œblind = FALSEâ€. 
To  remove  unwanted  variability  driven  by  technical  factors  in  the  cohort  6,  the 
removeBatchEffect function (limma R library v 3.50.3)48 was used with the original dataset 
specified as the variable to consider in the linear model. 
The package ggplot2 (v 3.3.5)49 was used for graphical representation. 
 
Comparison of ADAMTSL1-High and ADAMTSL1-Low samples 
Definition of ADAMTSL1 expression groups 
In both cohorts 4 and 6, patients were stratified according to ADAMTSL1 expression level: 
samples with ADAMTSL1 levels > 3rd quartile (Q3) formed the high expression group, while 
samples with ADAMTSL1 levels < 1st quartile (Q1) formed the low expression group. For cohort 
5,  the  KaplanScan  method  implemented  by  R2  was  used  to  identify  the  cutoff  of  the 
ADAMTSL1 probe cg14523394, separately for each histology (eRMS/aRMS). 
 
Survival analysis 
Kaplan-Meier survival analysis was run on cohorts 4 and 5 (ETABM-1202 and GSE167059) for 
which clinical data were available, using the R packages survminer (v 0.4.9)50 and survival (v 
3.3-1)51. Log-rank test was used to assess significance between the survival probability of 
ADAMTSL1 High samples and ADAMTSL1 Low samples, in FNRMS and FPRMS separately, for 
all survival analysis. 
 
TGF-Î² pathway activity 
The R package PROGENy (v 1.18.0)21 was used to assess the activity of the TGF-Î² pathway 
using default parameters. Boxplots were made with ggplot2 (v 3.3.5)49. 
 
Differential expression analysis and enrichment 
Differential expression analysis on cohort 4 was run with the R package limma (v 3.50.3) based 
on previously defined ADAMTSL1 expression groups, separately for FNRMS/FPRMS. Genes a 
with a raw p-value cutoff of 0.05 were considered as differentially expressed (DE), yielding 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
1095 DE genes. For RMS cohort 6, DESeq2 was used to identify differentially expressed genes 
between ADAMTSL1-high and ADAMTSL1-low samples, separately in FNRMS and FPRMS. The 
alpha parameter of the â€œresultsâ€ function was set to 0.05, and DE genes were identified with 
an adjusted p-value (FDR) cutoff of 0.05. 
The EnrichR package (v 3.0)52 was used separately on DE genes upregulated in ADAMTSL1-
high  samples  and  DE  genes  upregulated  in  ADAMTSL1-low  samples,  with  the  following 
databases: Gene Ontology (GO) Biological Process 2021, GO Molecular Function 2021, GO 
Cellular Compartment 2021, KEGG 2021 Human, MSigDB Hallmarks 2020, Reactome 2016 and 
ChEA 2016. 
 
Correlation analysis 
Correlations between ADAMTSL1 and all other genes in each fusion subtype (FPRMS/FNRMS) 
were assessed using Pearsonâ€™s coefficient. Genes were considered significantly correlated 
when unadjusted p-value < 0.05. Venn diagram representation of the significantly correlated 
genes identified was made with ggvenn (v 0.1.9)53. 
 
Statistical analyses 
For in vitro experiments, replicates signify independent experiments. For in vivo experiments, 
replicates signify individual muscles. All results were analysed using unpaired parametric 
analyses. Statistical significance was determined using two-sided Studentâ€™t t tests, or Welch t 
test in case of unequal variance.  
 
Data availability 
GSE109178  (cohort  1)  and  GSE28511  (cohort  3)  datasets  were  downloaded  on  GEO 
(www.ncbi.nlm.nih.gov/geo/).  Cohort  5  data  was  downloaded  on  R2  Cancer 
(https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). Raw CEL files of cohort 4 (accession code 
ETABM-1202)  were  downloaded  on  ArrayExpress 
(https://www.ebi.ac.uk/biostudies/arrayexpress). St Jude dataset (cohort 6) was downloaded 
on the St Jude Cloud platform (https://www.stjude.cloud). Newly generated RNA-seq data of 
the Inhouse cohort will be made available on GEO (cohort 2). 
 
 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
Acknowledgements 
We thank the patients and their families who consented to participate in this study, as well as 
the Ligue Nationale contre le Cancer, and the Ligue Contre le Cancer du RhÃ´ne, which provided 
the funding for this project. We also thank clinical teams from IHOPe (Institut d'HÃ©matologie 
et d'Oncologie PÃ©diatrique) and HFME (HÃ´pital Femme MÃ¨re Enfant â€“ HCL) for their support 
and contributions, as well as all the facilities from the CLB and CRCL. We are grateful to 
SÃ©verine Tabone-Eglinger, LoÃ¯c Sebileau and Anne-Sophie Bonne for their help with the 
management of regulatory procedures.  
 
 
   

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
FIGURE LEGENDS 
 
FIGURE 1: Loss of ADAMTSL1 induces mild skeletal muscle regeneration defects in mice. A. 
Scheme of Adamtsl1 exon 1 KO strategy and impact on expression of its expression in KO 
versus WT mice. RT-QPCR were performed on mice Quadriceps (QUAD) and Tibialis Anterior 
(TA) muscles. Results are mean +/-std, n=3. **: p<0.01, ***: p<0.001, t-test. B. Mean fiber size 
showing slight hypotrophy in ADAMTSL1 KO mice muscle at 6 and 12 months of age (left 
panels). 6mo: 6months-old mice. 12 mo: 12 months-old mice. Results are mean+/-std, indexed 
to mean of control animals; n=3, *: p<0.05, t-test. Representative images of Laminin/MYH4 
stainings are shown (right panel). C. Impaired muscle regeneration in Tibialis Anterior muscle 
of Adamtsl1 KO mice after an injury induced by cardiotoxin injection. Quantification of lipid 
droplets infiltrates in KO mice (n=4) compared to controls (n=4) (left panel). Results are means 
+/-std; p=0.07, t-test. Representative images of muscle histology and lipid droplets infiltrates 
(Sudan Black staining) in KO mice compared to controls are shown (right panel). D.p.i: Days 
post injury, H&E: Hematoxylin & Eosin, CTX: cardiotoxin. D. Absence of significant changes in 
the  fusion  index  of  satellite  cells  derived  from  ADAMTSL1  WT  and  KO  mice.  DM: 
Differentiation medium. Results are means +/-std. E. UMAP visualization of unified scRNA-seq 
data of skeletal muscle cell populations (left panel), showing that ADAMTSL1 is mostly 
expressed  in  Fibro-Adipogenic  Precursors  (FAP)  (right  panel).  F.  RT-qPCR  analysis  of 
ADAMTSL1 mRNA level in various cell populations FACS-sorted from Tibialis Anterior muscle. 
Muscles were analysed 0, 1, 2, 4, 7 and 14 days after injury (d.p.i). 
 
FIGURE 2: ADAMTSL1 is linked to the regulation of TGF-Î² pathway in skeletal muscles. A. 
Expression of ADAMTSL1 in skeletal muscle samples from patients with Duchenne dystrophy. 
Analysis was made from GSE109178 microarray cohort (cohort 1). Disease grade was reported 
in clinical data. **: p<0.01, ***: p<0.001, t-test. B. Colocalization of ADAMTSL1 and LTBP1 in 
skeletal muscles from patients with muscle dystrophy. ADAMTSL1 and LTBP1 are respectively 
stained in red and green. Nuclei are counterstained in blue. Representative confocal images 
of a muscle biopsy from a patient with Ullrich Congenital Muscular Dystrophy are shown. C. 
Correlation between ADAMTSL1 expression and TGF-Î² pathway activity inferred from a 
specific gene response signature using PROGENy algorithm in skeletal muscles from patients 
with Duchenne dystrophy (cohort 1). The Pearson correlation coefficient is shown for each 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
disease grade, with its associated p-value. D. Modifications of TGF-Î² target genesâ€™ expression 
in ADAMTSL1 KO versus WT animals. TGF-Î² targets were quantified by Q-RT-PCR in skeletal 
Tibialis Anterior muscle from 3 months-old mice, using the dedicated kit from Qiagen. Results 
are mean+/-std; n=3. *: p<0.05, one-sided t-test. 
 
FIGURE 3: ADAMTSL1 expression is a good prognostic marker associated with neural-like 
phenotype in FP-RMS. A. Expression levels of ADAMTSL1 between normal muscles and FP-
RMS samples (cohort 2, RNAseq). Differences between groups were tested using wilcoxon 
signed-rank test with associated statistical probability displayed on top. B-C. Survival analyses 
of ADAMTSL1 expression value in FP-RMS samples (B) and FN-RMS samples (C) (cohort 4). 
Kaplan-Meier curves were generated between ADAMTSL1-high and -low groups, generated as 
defined in Material and Methods section. Differences of overall survival probability between 
both groups were tested using log-rank tests and associated statistical probabilities are 
displayed on the graph, for both FP- and FN-RMS cohorts. Number of patients at risk are 
indicated  in  the  tables  below  the  curves.  D.  Heatmap  representing  the  transcriptomic 
expression  levels  of  apoptotic  genes  significantly  differentially  expressed  between 
ADAMTSL1-high and low groups of FP-RMS (cohort 4). Normalized and scaled gene expression 
levels are color-coded with a blue (low expression) to red (high expression) gradient. Samples 
in  columns  are  clustered  using  Ward's  method  on  the  inverse  Spearmanâ€™s  correlation 
coefficient matrix. E. Functional enrichment between ADAMTSL1-high and -low groups of FP-
RMS  (see  Material  and  Methods).  GO_Biological_Process_2021  Enrichment  reveals  a 
significant enrichment in neural-related pathways in ADAMTSL1-high group. F. Images of a 
transwell migration assay with RH3 FP-RMS cells cultured for 24â€‰h with 3T3 fibroblasts cells 
overexpressing, or not, ADAMTSL1 (left panel). Graphs represent mean values +/-std; n=3. *: 
p<0.05, t-test.G. Functional enrichment between ADAMTSL1-high and -low groups of FP-RMS 
(see Material and Methods). ChEA_2016 Enrichment reveals a significant enrichment notably 
in SMAD2/3/4 targets in ADAMTSL1-high group. 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
References 
1.  Saab, R., Spunt, S. L. & Skapek, S. X. Myogenesis and rhabdomyosarcoma the Jekyll and 
Hyde of skeletal muscle. Curr. Top. Dev. Biol. 94, 197â€“234 (2011). 
2.  Skapek, S. X. et al. Rhabdomyosarcoma. Nat. Rev. Dis. Primer 5, 1 (2019). 
3.  Fanzani, A., Monti, E., Donato, R. & Sorci, G. Muscular dystrophies share pathogenetic 
mechanisms with muscle sarcomas. Trends Mol. Med. 19, 546â€“554 (2013). 
4.  Chamberlain, J. S., Metzger, J., Reyes, M., Townsend, D. & Faulkner, J. A. Dystrophin-
deficient  mdx  mice  display  a  reduced  life  span  and  are  susceptible  to  spontaneous 
rhabdomyosarcoma. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 21, 2195â€“2204 (2007). 
5.  Chandler, E., Rawson, L., Debski, R., McGowan, K. & Lakhotia, A. Rhabdomyosarcoma 
in a Patient With Duchenne Muscular Dystrophy: A Possible Association. Child Neurol. Open 8, 
2329048X211041471 (2021). 
6.  Sirvent, N., Trassard, M., Ebran, N., Attias, R. & Pedeutour, F. Fusion of EWSR1 with the 
DUX4 facioscapulohumeral muscular dystrophy region resulting from t(4;22)(q35;q12) in a 
case of embryonal rhabdomyosarcoma. Cancer Genet. Cytogenet. 195, 12â€“18 (2009). 
7.  Sharma, V., Harafuji, N., Belayew, A. & Chen, Y.-W. DUX4 differentially regulates 
transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells. PloS One 8, e64691 
(2013). 
8.  Chen, J. L., Colgan, T. D., Walton, K. L., Gregorevic, P. & Harrison, C. A. The TGF-Î² 
Signalling Network in Muscle Development, Adaptation and Disease. Adv. Exp. Med. Biol. 900, 
97â€“131 (2016). 
9.  Juban, G. et al. AMPK Activation Regulates LTBP4-Dependent TGF-Î²1 Secretion by Pro-
inflammatory Macrophages and Controls Fibrosis in Duchenne Muscular Dystrophy. Cell Rep. 
25, 2163-2176.e6 (2018). 
10.  Waning, D. L. et al. Excess TGF-Î² mediates muscle weakness associated with bone 
metastases in mice. Nat. Med. 21, 1262â€“1271 (2015). 
11.  Principe,  D.  R.  et  al.  TGF-Î²:  duality  of  function  between  tumor  prevention  and 
carcinogenesis. J. Natl. Cancer Inst. 106, djt369 (2014). 
12.  BouchÃ©,  M.  et  al.  TGF-beta  autocrine  loop  regulates  cell  growth  and  myogenic 
differentiation in human rhabdomyosarcoma cells. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 
14, 1147â€“1158 (2000). 
13.  Horiguchi, M., Ota, M. & Rifkin, D. B. Matrix control of transforming growth factor-Î² 
function. J. Biochem. (Tokyo) 152, 321â€“329 (2012). 
14.  Grass, B. et al. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and 
AP2beta as biomarkers for rhabdomyosarcoma diagnostics. Histopathology 54, 873â€“879 
(2009). 
15.  Hirohata, S. et al. Punctin, a novel ADAMTS-like molecule, ADAMTSL-1, in extracellular 
matrix. J. Biol. Chem. 277, 12182â€“12189 (2002). 
16.  Le Goff, C. et al. ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for 
ADAMTS-like  proteins  in  TGF-beta  bioavailability  regulation.  Nat.  Genet.  40,  1119â€“1123 
(2008). 
17.  Tsutsui, K. et al. ADAMTSL-6 is a novel extracellular matrix protein that binds to fibrillin-
1 and promotes fibrillin-1 fibril formation. J. Biol. Chem. 285, 4870â€“4882 (2010). 
18.  Rypdal,  K.  B.  et  al.  ADAMTSL3  knock-out  mice  develop  cardiac  dysfunction  and 
dilatation with increased TGFÎ² signalling after pressure overload. Commun. Biol. 5, 1â€“15 
(2022). 
19.  Morgan, J., Butler-Browne, G., Muntoni, F., Patel, K., & skeletal muscle stem cells 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
involvement in pathology study group. 240th ENMC workshop: The involvement of skeletal 
muscle stem cells in the pathology of muscular dystrophies 25-27 January 2019, Hoofddorp, 
The Netherlands. Neuromuscul. Disord. NMD 29, 704â€“715 (2019). 
20.  MÃ¡zala, D. A. et al. TGF-Î²-driven muscle degeneration and failed regeneration underlie 
disease onset in a DMD mouse model. JCI Insight 5, e135703, 135703 (2020). 
21.  Schubert, M. et al. Perturbation-response genes reveal signaling footprints in cancer 
gene expression. Nat. Commun. 9, 20 (2018). 
22.  Ceco, E. & McNally, E. M. Modifying muscular dystrophy through transforming growth 
factor-Î². FEBS J. 280, 4198â€“4209 (2013). 
23.  Patel, A. G. et al. The myogenesis program drives clonal selection and drug resistance 
in rhabdomyosarcoma. Dev. Cell 57, 1226-1240.e8 (2022). 
24.  Wei, Y. et al. Single-cell analysis and functional characterization uncover the stem cell 
hierarchies and developmental origins of rhabdomyosarcoma. Nat. Cancer 3, 961â€“975 (2022). 
25.  Wang, H. et al. Systematic analysis of the TGF-Î²/Smad signalling pathway in the 
rhabdomyosarcoma cell line RD. Int. J. Exp. Pathol. 84, 153â€“163 (2003). 
26.  Wang, S. et al. TGF-beta1 signal pathway may contribute to rhabdomyosarcoma 
development by inhibiting differentiation. Cancer Sci. 101, 1108â€“1116 (2010). 
27.  Gatz, S. A. et al. A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of 
Rhabdomyosarcomas. Front. Oncol. 9, 1271 (2019). 
28.  Elbitar, S. et al. Pathogenic variants in THSD4, encoding the ADAMTS-like 6 protein, 
predispose to inherited thoracic aortic aneurysm. Genet. Med. Off. J. Am. Coll. Med. Genet. 
23, 111â€“122 (2021). 
29.  Rypdal, K. B. et al. The extracellular matrix glycoprotein ADAMTSL2 is increased in heart 
failure and inhibits TGFÎ² signalling in cardiac fibroblasts. Sci. Rep. 11, 19757 (2021). 
30.  Ceco, E. et al. Targeting latent TGFÎ² release in muscular dystrophy. Sci. Transl. Med. 6, 
259ra144 (2014). 
31.  Camboni, M., Hammond, S., Martin, L. T. & Martin, P. T. Induction of a regenerative 
microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in 
p53-deficient mice. J. Pathol. 226, 40â€“49 (2012). 
32.  Seetharaman,  A.  et  al.  MADD-4  is  a  secreted  cue  required  for  midline-oriented 
guidance in Caenorhabditis elegans. Dev. Cell 21, 669â€“680 (2011). 
33.  Campbell, V. T. et al. Hedgehog pathway inhibition in chondrosarcoma using the 
smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth. Mol. Cancer Ther. 13, 
1259â€“1269 (2014). 
34.  Kneppers,  A.  et  al.  AMPKÎ±2  is  a  skeletal  muscle  stem  cell  intrinsic  regulator  of 
myonuclear  accretion.  2022.11.02.514556  Preprint  at 
https://doi.org/10.1101/2022.11.02.514556 (2022). 
35.  Castets et al., P. Selenoprotein N is dynamically expressed during mouse development 
and detected early in muscle precursors - PubMed. BMC Dev (2009). 
36.  Castets, P. et al. Satellite cell loss and impaired muscle regeneration in selenoprotein 
N deficiency. Hum. Mol. Genet. 20, 694â€“704 (2011). 
37.  McArthur, S. et al. Annexin A1 drives macrophage skewing to accelerate muscle 
regeneration through AMPK activation. J. Clin. Invest. 130, 1156â€“1167 (2020). 
38.  McKellar, D. W. et al. Large-scale integration of single-cell transcriptomic data captures 
transitional progenitor states in mouse skeletal muscle regeneration. Commun. Biol. 4, 1280 
(2021). 
39.  Missiaglia, E. et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. 
Oncol. Off. J. Am. Soc. Clin. Oncol. 30, 1670â€“1677 (2012). 
40.  Irizarry,  R.  A.  et  al.  Exploration,  normalization,  and  summaries  of  high  density 
oligonucleotide array probe level data. Biostat. Oxf. Engl. 4, 249â€“264 (2003). 
41.  McLeod, C. et al. St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. 
Cancer Discov. 11, 1082â€“1099 (2021). 
42.  Andrews S. (2010) - FastQC A Quality Control tool for High Throughput Sequence Data. 
https://www.bioinformatics.babraham.ac.uk/projects/fastqc/. 
43.  Cutadapt  removes  adapter  sequences  from  high-throughput  sequencing  reads  | 
Martin  |  EMBnet.journal. 
https://journal.embnet.org/index.php/embnetjournal/article/view/200/479. 
44.  Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma. Oxf. Engl. 29, 15â€“
21 (2013). 
45.  Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with high-
throughput sequencing data. Bioinforma. Oxf. Engl. 31, 166â€“169 (2015). 
46.  org.Hs.eg.db. Bioconductor http://bioconductor.org/packages/org.Hs.eg.db/. 
47.  Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion 
for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014). 
48.  Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing 
and microarray studies. Nucleic Acids Res. 43, e47 (2015). 
49.  Wickham, H. Create Elegant Data Visualisations Using the Grammar of Graphics. 
https://ggplot2.tidyverse.org/?fbclid=IwAR2fH4WF3pUlq9kvhpXelYTg_6fqnZXOrlj526PUXZ7c
5rMoteUFY4782yg. 
50.  Kassambara, A., Kosinski, M., Biecek, P. & Fabian, S. survminer: Drawing Survival Curves 
using â€˜ggplot2â€™. (2021). 
51.  Therneau, T. M., until 2009), T. L. (original S.->R port and R. maintainer, Elizabeth, A. & 
Cynthia, C. survival: Survival Analysis. (2023). 
52.  Jawaid, W. enrichR: Provides an R Interface to â€˜Enrichrâ€™. (2022). 
53.  Yan, L. ggvenn: Draw Venn Diagram by â€˜ggplot2â€™. (2021). 
 
 

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
Figure 1.  (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
A B
Laminin / MHCIIa
A
N
R
m T
W
1 
sl
mt
a
d
A
ve  O
WT ati K
KO Rel
C D
28 d.p.i
Sudan Black H&E
30 000 È¼/cm2
T
W
DM 0h
O
K
2288  dd..pp.i.i. 48h
E F
Adamtsl1
umap_harmony_2umap_harmony_2âˆ’âˆ’âˆ’111505500Myoâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—uâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Mâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—(â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—yâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—yâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—pâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—uâ—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—câ—â—â—â—â— â—â—â—Ilâ—eIxâ—Nâ—iT â—)â—â—â—(K BTâ—â—â—â—CMâ—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—yâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—pâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—yâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Mâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—sâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—bâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—sâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—2Isâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—aâ—â—â—â—â—â—â—â—â—â—â—â—â—bâ—â—â—â—â—â—â—â—â—â—â—â—â—Mâ—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—sâ—â—â—â—â—â—â—â—â—M)â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—2â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Mâ—â—â—â—â—â—â—â—â—sâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—aâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—/â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Mâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Pâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—uâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Sâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—eaâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Mâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—ncâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—.â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—uâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—gâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—(â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—sâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—.â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Fâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—yâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—xâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—(â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—pâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Aâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—3â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—hâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Pâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—yâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—sâ—â—â—â—â—â—â—â—â—â—â—â—â—xâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Sâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—ssâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—3â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—sâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—1â—â—â—â—â—â—â—Fâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—mâ—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Aâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—_â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—(â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—(â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Pâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Pâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—1â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Dâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—_â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—sâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—)â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—fâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—hâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—âˆ’â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—aâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—hâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—(â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Aâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—mâ—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—)â—â—â—â—dâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Mâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—dâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—mâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—mâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Mâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—uâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—pâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—aâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—sâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—dâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Fâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—gâ—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Mâ—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Aâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—uâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—yâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Pâ—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—&â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—)â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—yaâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—sâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—gâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Pâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—)eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—)â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—(â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Sâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—yâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—(â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—Pâ—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—dâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—aâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—mâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—yâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—(â—â—â—â—ttâ—â—â—â—â—â—â—tâ—â—â—Câ—râ—â—hâ—â—â—â—â—â—â—â—e)â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—xâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—sâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—Eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—aâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—1â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—gâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—0â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—nâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—(â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—)â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—dâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Câ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—+â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—dâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—)â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—aâ—â—â—â—â—â—â—â—â—â—oâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—hâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—pâ—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—hâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—aâ—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—aâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—aâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—yâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—lâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—(â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â— â—â—â—â—â—â—)â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Aâ—â—â—â—â—â—â—â—â—(â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—Vâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—râ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—tâ—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—â—eâ—â—â—â—â—â—â—â—â—â—â—â—iâ—â—â—nry)) 2_ynomrah_pamuumap_harmony_2âˆ’âˆ’âˆ’111505500 0123 ANRm 1LSTMADA evitaleRrebmunllec*321...5553215Ã—Ã—Ã—Ã—Ã—Ã—Ã—1111111000000007777776 0 1 2d.p.i4. 7 14 FSENMMAACPPPPT  apnroti
âˆ’15 âˆ’10 âˆ’5 0 5 10 15 âˆ’15 âˆ’10 âˆ’5 0 5 10 15
umumaapp__hahrmaornmy_o1ny_1 umuampap__hhaarmromnyo_1ny_1

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
Figure 2.  (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
A B
***
8 p=0.067
n **
o
si
s
e
pr6
x
e
d 
e
s
ali
m
or
1 n4
L
S
T
M
A
D
A
2
0
Mild Moderate Severe
C D
Mild Moderate Severe
R2=0.53, p=0.036 R2=0.62, p=0.074 R2=0.33, p=0.175
2
y 1
vit
cti
a
y 
a
w
h
pat 0
b 
F
G
T
âˆ’1
âˆ’2
0 2 4 6 0 2 4 6 0 2 4 6
ADAMTSL1 expression

NEW PAGE

bioRxiv preprint doi: https://doi.org/10.1101/2023.03.07.531559; this version posted March 8, 2023. The copyright holder for this preprint
Figure 3. 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
A B C
12 p = 7.6eâˆ’05 Strata+ ADAMTSL1=High + ADAMTSL1=Low Strata+ ADAMTSL1=High + ADAMTSL1=Low
1.00 ++ + + 1.00 +
ession obability0.75 + + obability0.75 ++++++++++++ + + + + + + ++
1 normalised expr 180 Overall Survival pr00..2550 pL o=g âˆ’0.r0a0n0k3+3+ + + Overall Survival pr00..2550 pL o=g âˆ’0.r9a6nk
SL 0.00 0.00
MT 0 3 Time in6 years 9 12 0 2.5 Time in5 years 7.5 10
A Number at risk Number at risk
D
A ADAMTSL1=High 11 8 2 1 0 ADAMTSL1=High 14 11 6 3 0
6 ADAMTSL1=Low 11 4 0 0 0 ADAMTSL1=Low 14 8 2 2 0
0 3 6 9 12 0 2.5 5 7.5 10
Embryonal muscle RMS Time in years Time in years
D E GO_Biological_Process_2021
generation of neurons (GO:0048699)
axonogenesis (GO:0007409)
axon guidance (GO:0007411)
neuron projection development (GO:003117...
neuron migration (GO:0001764)
Fusion status neuron projection morphogenesis (GO:0048...
FPRMS chemical synaptic transmission (GO:00072...
ADAMTSL1	 neuron differentiation (GO:0030182)
p-value
expression group ms synapse assembly (GO:0007416)
LHoigwh d ter ganglion development (GO:0061548) 0.00005
e
Cexepnrteesresido nvst	 Enrich neuron acxeollnâˆ’ cdeelvl ealdohpemseionnt  ((GGOO::00006017515684)) 00..0000001150
4 sympathetic nervous system development (...
2
0 neuron development (GO:0048666)
âˆ’2
âˆ’4 cell junction assembly (GO:0034329)
regulation of neuron projection developm...
anterograde transâˆ’synaptic signaling (GO...
homophilic cell adhesion via plasma memb...
SJRHB038_RSJRHB031244_D2SJRHB031244_D1SJRHB030264_D1SJRHB010_DSJRHB030858_D1SJRHB010468_D1SJRHB030787_D1SJRHB030495_D1SJRHB031117_D1SJRHB008_DSJRHB030476_D2SJRHB015_DSJRHB030476_D1SJRHB031848_D1SJST030705_D1SJRHB031225_D1SJRHB019_D negative reagxuolna teioxnte onfs nioenu (rGonO d:0if0fe4r8e6n7ti5..). 0.0 2.5 G5e.0ne cou7n.t5 10.0 12.5
F G ChEA_2016
SUZ12 20075857 ChIPâˆ’Seq MESCs Mouse
REST 21632747 ChIPâˆ’Seq MESCs Mouse
RH30 EZH2 27294783 Chipâˆ’Seq ESCs Mouse
3T3-WT
PAX3âˆ’FKHR 20663909 ChIPâˆ’Seq RHABDOMYOSAR...
MTF2 20144788 ChIPâˆ’Seq MESCs Mouse
TOP2B 26459242 ChIPâˆ’Seq MCFâˆ’7 Human
SOX2 21211035 ChIPâˆ’Seq LN229 Gbm
CTBP1 25329375 ChIPâˆ’Seq LNCAP Human
RH30 p-value
3T3-ATL1 ms SMAD4 21799915 ChIPâˆ’Seq A2780 Human
ed ter SMAD2/3 21741376 ChIPâˆ’Seq EPCs Human 21eeâˆ’âˆ’0077
Enrich JASRUIDZ21 22 01087659825477 4C hCIhPIâˆ’PSâˆ’eSqe qM MESECFss  MMoouussee 3eâˆ’07
4eâˆ’07
SUZ12 18692474 ChIPâˆ’Seq MESCs Mouse
TCF4 23295773 ChIPâˆ’Seq U87 Human
WT1 25993318 ChIPâˆ’Seq PODOCYTE Human
OLIG2 23332759 ChIPâˆ’Seq OLIGODENDROCYTES...
SUZ12 18974828 ChIPâˆ’Seq MESCs Mouse
YAP1 20516196 ChIPâˆ’Seq MESCs Mouse
RCOR3 21632747 ChIPâˆ’Seq MESCs Mouse
TAL1 26923725 Chipâˆ’Seq HEMANGIOBLAST Mou...
0 25 50 75
Gene count

NEW PAGE